Abstract: A system for protecting the battery of a vehicle includes a device (1) for electrically disconnecting of connecting the battery (BA) with respect to an electric load (CS). The device (1) includes a switch (20, 21) and a microprocessor control circuit (15). The control circuit (15) includes a unit for calculating a mean value of the voltage of the battery (BA) and comparing it with a threshold value, in order to control the switch (20, 21). The threshold value is variable as a function of the ambient temperature and the time of inactivity of the motor. The switch includes a bistable electromagnetic arrangement, capable of passing from a first to a second stable condition following a pulse generated by the control circuit (15).

Abstract: A multimer protein molecule comprising at least a first amino acid sequence having substantially the sequence of one of the Parietaria judaica major allergens and a second amino acid sequence having substantially the sequence of one of the Parietaria judaica major allergens Par j 1 or Par j 2, and a third sequence of one of the Parietaria judaica major allergens Par j 1 or Par j 2. The molecule is also mutated in the amino acid region corresponding to loop 1, so that is hypoallergenic. The molecule can be utilized for medical use as a hypoallergenic agent.

Abstract: A system for protecting the battery of a vehicle comprises a device (1) for electrically disconnecting of connecting the battery (BA) with respect to an electric load (CS); the device (1) comprises switch means (20, 21) and a microprocessor control circuit (15). The control circuit (15) comprises means for calculating a mean value of voltage of the battery (BA) and comparing it with a threshold value, in order to control the switch means (20, 21). The threshold value is variable as a function of the ambient temperature and the time of inactivity of the motor, and the switch means comprises a bistable electromagnetic arrangement, capable of passing from a first to a second stable condition following a pulse generated by the control circuit (15).

Abstract: Carrier particles, for use in the preparation of powdery mixtures for administration by inhalation, and having a median diameter of greater than 90 microns and a surface rugosity expressed as the fractal dimension of less than or equal to 1.1, may be prepared by subjecting particles having a median diameter of greater than 90 microns to repeated stages of wetting with a solvent and drying.

Abstract: The present invention relates to hypoallergenic variants of ns-LTPs allergens, to pharmaceutical compositions comprising them and to the use of such variants for the preparation of medicaments suitable in the treatment and in the prevention of the allergic forms associated with an ns-LTP allergen, in particular to the allergen corresponding to the variant used.

Abstract: The present invention concerns drug formulae for nasal administration and insufflators filled with said formula. The present invention also concerns methods for making said formulae available as well as primary particles for obtaining chimerical agglomerates that can be used in said formulae.

Abstract: The present invention concerns an innovative pharmaceutical form for controlled drug release. In particular, the present invention refers to systems obtained by the assembly of individual release modules, of which the capacity to release the drug in time and in space depends on the way in which the modules have been assembled. The modular structure offers high reproducibility of manufacture and flexibility of release.

Abstract: A method for producing ceramic micromanufactured items comprises the following stages: a starting material constituting at least a micromanufactured item (1) is prepared and used to from the micromanufactured item (1); said starting material includes at least a pre-ceramic polymer, and the method further comprises a stage in which the inner structure of the starting material is modified, said structure being turned from a polymeric structure to a ceramic structure after the forming stage of said micromanufactured item (1).

Abstract: Carriers for use in the preparation of mixtures for inhalation powders intended for pulmonary administration of micronized drugs by means of a dry powder inhaler and the method for their preparation are described.

Abstract: Sucralfate gel in the dry state in porous granular form having a particle-size distribution of between 100 and 1000 &mgr;m, an apparent density of the powder bed of between 0.7 and 0.9 g/ml, a settling index of between 5 and 15%, and a residual humidity of between 5 and 15%, and the corresponding process of preparation, which comprises a treatment with microwaves of a diluted solution of powdered sucralfate gel, with a sucralfate titer of between 20 and 70 wt. %. This solid product may be advantageously used in the preparation of solid pharmaceutical compositions that contain it as single active principle, or else as coating of solid compositions that contain, as active principle, a substance that may cause lesions to the gastric mucosa.

Abstract: A pharmaceutical formulation which comprises a parenterally acceptable carrier or diluent, estramustine phosphate and a sulfoalkyl ether cyclodextrin. The formulation can be administered according to a combined chemotherapy regimen in association with one or more chemotherapeutic agents. The formulation also enables estramustin phosphate to be administered with no side effects at the site of injection.

Abstract: Sucralfate gel in the dry state in porous granular form having a particle-size distribution of between 100 and 1000 &mgr;m, an apparent density of the powder bed of between 0.7 and 0.9 g/ml, a settling index of between 5 and 15%, and a residual humidity of between 5 and 15%, and the corresponding process of preparation, which comprises a treatment with microwaves of a diluted solution of powdered sucralfate gel, with a sucralfate titre of between 20 and 70 wt. %. This solid product may be advantageously used in the preparation of solid pharmaceutical compositions that contain it as single active principle, or else as coating of solid compositions that contain, as active principle, a substance that may cause lesions to the gastric mucosa.

Abstract: Single-layer film for active ingredients dermal and transdermal administration containing at least an active ingredient, a film-forming agent, and a hydrophilic adhesive polymer.

Abstract: The present invention relates to the use of arginine and, more in particular, to the injectable formulations for intravenous use comprising it, in the prevention and treatment of the side effects associated with the extravasation of drugs administered by intravenous route.

Abstract: Sucralfate gel in the dry state in porous granular form having a particle-size distribution of between 100 and 1000 &mgr;m, an apparent density of the powder bed of between 0.7 and 0.9 g/ml, a settling index of between 5 and 15%, and a residual humidity of between 5 and 15%, and the corresponding process of preparation, which comprises a treatment with microwaves of a diluted solution of powdered sucralfate gel, with a sucralfate titre of between 20 and 70 wt. %. This solid product may be advantageously used in the preparation of solid pharmaceutical compositions that contain it as single active principle, or else as coating of solid compositions that contain, as active principle, a substance that may cause lesions to the gastric mucosa.

Abstract: The present invention relates to the use of an isolated allergen component in a serological assay for improved precision in the identification of the actual sensitizer in diagnosis of allergy. This enables not only adequate measures for avoidance of the causative agent but also appropriate selection of treatment of the allergic disease.

Abstract: A method of forming a doped region in an integrated circuit which includes a matrix of memory cells and lightly-doped drain transistors and which is fabricated by means of a process providing for a Self-Aligned Source masked etch and implant and for a selective salicidation of some doped regions, the doped region suitable for forming an integrated resistor and/or an abrupt-profile source/drain region of a transistor. The doped region is formed by introducing into a semiconductor layer of a first conductivity type a dopant of a second conductivity type and exploiting the SAS masked implant used to form source regions of the matrix of memory cells. At least a portion of a surface of the doped region is prevented from being salicidated by using as a protective mask a portion of a dielectric layer from which insulating sidewall spacers for the LDD transistors are formed.

Abstract: A method and a related circuit structure are described for improving the effectiveness of ESD protection in circuit structures realized in a semiconductor substrate overlaid with an epitaxial layer and including at least one ESD protection lateral bipolar transistor realized in the surface of the epitaxial layer. The method consists of forming under the transistor an isolating well that isolates the transistor from the substrate. Advantageously, the transistor can be fully isolated from the substrate by first and second N wells which extend from the surface of the epitaxial layer down to and in contact with the buried well.

Abstract: A method and a related circuit structure are described for improving the effectiveness of ESD protection in circuit structures realized in a semiconductor substrate overlaid with an epitaxial layer and including at least one ESD protection lateral bipolar transistor realized in the surface of the epitaxial layer. The method consists of forming under the transistor an isolating well that isolates the transistor from the substrate.

Abstract: An ESD protection network protects a CMOS circuit structure integrated in a semiconductor substrate. The circuit structure includes discrete circuit blocks formed in respective substrate portions which are electrically isolated from one another and independently powered from at least one primary voltage supply having a respective primary ground, and from at least one secondary voltage supply having a respective secondary ground. This network includes a first ESD protection element for an input stage of the circuit structure; a second ESD protection element for an output stage of the circuit structure, the first and second protection elements having an input/output pad of the integrated circuit structure in common; a first ESD protection element between the primary supply and the primary ground; and a second ESD protection element between the secondary supply and the secondary ground.